Pironi, LorisSteiger, EzraBrandt, ChrisofferJoly, FranciscaWanten, GeertChambrier, CecileAimasso, UmbertoSasdelli, Anna SimonaZeraschi, SarahKelly, DarleneSzczepanek, KingaJukes, AmeliaDi-Caro, SimonaTheilla, MiriamKunecki, MarekDaniels, JoanneSerlie, MireillePoullenot, FlorianWu, JianCooper, Sheldon CRasmussen, Henrik HCompher, CharleneSeguy, DavidCrivelli, AdrianaPagano, Maria CHughes, Sarah-JaneGuglielmi, Francesco WKozjek, Nada RotovnikSchneider, Stéphane MGillanders, LynEllegard, LarsThibault, RonanMatras, PrzemysławZmarzly, AnnaMatysiak, KonradVan Gossum, AndreForbes, AlastairWyer, NicolaTaus, MarinaVirgili, Nuria MO'Callaghan, MargieChapman, BrookeOsland, EmmaCuerda, CristinaSahin, PeterJones, LynnWon-Lee, Andre DongMasconale, LuisaOrlandoni, PaoloIzbeki, FerencSpaggiari, CorradoBueno, MartaDoitchinova-Simeonova, MaryanaGarde, CarmenSerralde-Zuñiga, Aurora EOlveira, GabrielKrznaric, ZeljkoCzako, LaszloKekstas, GintautasSanz-Paris, AlejandroJauregui, Estrella PetrinaMurillo, Ana ZugastiSchafer, EszterArends, JannSuarez-Llanos, Jose PLal, Simon2023-01-252023-01-252019-03-25Pironi L, Steiger E, Brandt C, Joly F, Wanten G, Chambrier C, et al. Home parenteral nutrition provision modalities for chronic intestinal failure in adult patients: An international survey. Clin Nutr. 2020 Feb;39(2):585-591http://hdl.handle.net/10668/13844The safety and effectiveness of a home parenteral nutrition (HPN) program depends both on the expertise and the management approach of the HPN center. We aimed to evaluate both the approaches of different international HPN-centers in their provision of HPN and the types of intravenous supplementation (IVS)-admixtures prescribed to patients with chronic intestinal failure (CIF). In March 2015, 65 centers from 22 countries enrolled 3239 patients (benign disease 90.1%, malignant disease 9.9%), recording the patient, CIF and HPN characteristics in a structured database. The HPN-provider was categorized as health care system local pharmacy (LP) or independent home care company (HCC). The IVS-admixture was categorized as fluids and electrolytes alone (FE) or parenteral nutrition, either commercially premixed (PA) or customized to the individual patient (CA), alone or plus extra FE (PAFE or CAFE). Doctors of HPN centers were responsible for the IVS prescriptions. HCC (66%) was the most common HPN provider, with no difference noted between benign-CIF and malignant-CIF. LP was the main modality in 11 countries; HCC prevailed in 4 European countries: Israel, USA, South America and Oceania (p  This is the first study to demonstrate that HPN provision and the IVS-admixture differ greatly among countries, among HPN centers and between benign-CIF and cancer-CIF. As both HPN provider and IVS-admixture types may play a role in the safety and effectiveness of HPN therapy, criteria to homogenize HPN programs are needed so that patients can have equal access to optimal CIF care.enCancerHome parenteral nutritionIntestinal failureIntravenous supplementationChronic DiseaseCross-Sectional StudiesFemaleHealth SurveysHumansInternationalityIntestinal DiseasesMaleMiddle AgedParenteral Nutrition, HomeTreatment Outcomeresearch article30992207Restricted AccessInsuficiencia IntestinalAtención a la SaludFarmaciaNutrición ParenteralElectrólitosNutrición Parenteral en el Domicilio10.1016/j.clnu.2019.03.0101532-1983http://diposit.ub.edu/dspace/bitstream/2445/173307/3/PironiL.pdf